These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20385747)

  • 1. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Halfdanarson TR; Muders MH; Ames MM
    Pancreas; 2013 Apr; 42(3):411-21. PubMed ID: 23211371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
    Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.
    Li CF; Huang WW; Wu JM; Yu SC; Hu TH; Uen YH; Tian YF; Lin CN; Lu D; Fang FM; Huang HY
    Clin Cancer Res; 2008 Dec; 14(23):7822-31. PubMed ID: 19047110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Terry J; Lubieniecka JM; Kwan W; Liu S; Nielsen TO
    Clin Cancer Res; 2005 Aug; 11(15):5631-8. PubMed ID: 16061882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
    Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
    Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A; Fowler J; Hawkins L; Lamers F; Teja B; Incoronato A; Anderson R; Narendran A
    J Exp Ther Oncol; 2008; 7(3):183-93. PubMed ID: 19066127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinases in sinonasal undifferentiated carcinomas--evaluation for EGFR, c-KIT, and HER2/neu expression.
    Chernock RD; Perry A; Pfeifer JD; Holden JA; Lewis JS
    Head Neck; 2009 Jul; 31(7):919-27. PubMed ID: 19283847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
    Bergmann F; Breinig M; Höpfner M; Rieker RJ; Fischer L; Köhler C; Esposito I; Kleeff J; Herpel E; Ehemann V; Friess H; Schirmacher P; Kern MA
    Am J Gastroenterol; 2009 Jan; 104(1):171-81. PubMed ID: 19098866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
    Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
    Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
    Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
    Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S; Frkovic-Grazio S; Lamovec J; Serdarevic F; Gurjeva O; Palazzo J; Bilalovic N; Lee LM; Gatalica Z
    Hum Pathol; 2010 Nov; 41(11):1617-23. PubMed ID: 20688355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.